Sergio Vañó-Galván1, Rodrigo Pirmez2, Angela Hermosa-Gelbard3, Óscar M Moreno-Arrones3, David Saceda-Corralo3, Rita Rodrigues-Barata4, Juan Jimenez-Cauhe5, Wei L Koh6, Janina E Poa7, Rebekka Jerjen7, Lara Trindade de Carvalho7, Jared Marc John7, Corina I Salas-Callo2, Colombina Vincenzi8, Lu Yin9, Kristen Lo-Sicco9, Anna Waskiel-Burnat10, Michela Starace11, Jose Luis Zamorano12, Pedro Jaén-Olasolo3, Bianca Maria Piraccini11, Lidia Rudnicka10, Jerry Shapiro9, Antonella Tosti13, Rodney Sinclair7, Bevin Bhoyrul7. 1. #TricoHRC Research Group, Trichology Unit, Dermatology Department, Ramón y Cajal University Hospital, Instituto Ramon y Cajal de Investigación Sanitaria, University of Alcala, Madrid, Spain; Trichology and Hair Transplantation Unit, Grupo Pedro Jaen Clinic, Madrid, Spain. Electronic address: drsergiovano@gmail.com. 2. Instituto de Dermatologia Professor Rubem David Azulay, Santa Casa de Misericórdia do Rio de Janeiro, Rio de Janeiro, Brazil. 3. #TricoHRC Research Group, Trichology Unit, Dermatology Department, Ramón y Cajal University Hospital, Instituto Ramon y Cajal de Investigación Sanitaria, University of Alcala, Madrid, Spain; Trichology and Hair Transplantation Unit, Grupo Pedro Jaen Clinic, Madrid, Spain. 4. Trichology and Hair Transplantation Unit, Grupo Pedro Jaen Clinic, Madrid, Spain. 5. #TricoHRC Research Group, Trichology Unit, Dermatology Department, Ramón y Cajal University Hospital, Instituto Ramon y Cajal de Investigación Sanitaria, University of Alcala, Madrid, Spain. 6. Sinclair Dermatology, Melbourne, Australia; Department of Dermatology, Changi General Hospital, Singapore. 7. Sinclair Dermatology, Melbourne, Australia. 8. Nigrisoli Hospital, Bologna, Italy. 9. The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York. 10. Department of Dermatology, Medical University of Warsaw, Warsaw, Poland. 11. Dermatology -IRCCS Policlinico di Sant´Orsola, Department of Experimental, Diagnostic and Specialty Medicine (DIMES) Alma Mater Studiorum University of Bologna, Bologna, Italy. 12. Department of Cardiology, Ramón y Cajal Hospital, University of Alcala, Madrid, Spain. 13. Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida.
Abstract
BACKGROUND: The major concern regarding the use of low-dose oral minoxidil (LDOM) for the treatment of hair loss is the potential risk of systemic adverse effects. OBJECTIVE: To describe the safety of LDOM for the treatment of hair loss in a large cohort of patients. METHODS: Retrospective multicenter study of patients treated with LDOM for at least 3 months for any type of alopecia. RESULTS: A total of 1404 patients (943 women [67.2%] and 461 men [32.8%]) with a mean age of 43 years (range 8-86) were included. The dose of LDOM was titrated in 1065 patients, allowing the analysis of 2469 different cases. The most frequent adverse effect was hypertrichosis (15.1%), which led to treatment withdrawal in 14 patients (0.5%). Systemic adverse effects included lightheadedness (1.7%), fluid retention (1.3%), tachycardia (0.9%), headache (0.4%), periorbital edema (0.3%), and insomnia (0.2%), leading to drug discontinuation in 29 patients (1.2%). No life-threatening adverse effects were observed. LIMITATIONS: Retrospective design and lack of a control group. CONCLUSION: LDOM has a good safety profile as a treatment for hair loss. Systemic adverse effects were infrequent and only 1.7% of patients discontinued treatment owing to adverse effects.
BACKGROUND: The major concern regarding the use of low-dose oral minoxidil (LDOM) for the treatment of hair loss is the potential risk of systemic adverse effects. OBJECTIVE: To describe the safety of LDOM for the treatment of hair loss in a large cohort of patients. METHODS: Retrospective multicenter study of patients treated with LDOM for at least 3 months for any type of alopecia. RESULTS: A total of 1404 patients (943 women [67.2%] and 461 men [32.8%]) with a mean age of 43 years (range 8-86) were included. The dose of LDOM was titrated in 1065 patients, allowing the analysis of 2469 different cases. The most frequent adverse effect was hypertrichosis (15.1%), which led to treatment withdrawal in 14 patients (0.5%). Systemic adverse effects included lightheadedness (1.7%), fluid retention (1.3%), tachycardia (0.9%), headache (0.4%), periorbital edema (0.3%), and insomnia (0.2%), leading to drug discontinuation in 29 patients (1.2%). No life-threatening adverse effects were observed. LIMITATIONS: Retrospective design and lack of a control group. CONCLUSION:LDOM has a good safety profile as a treatment for hair loss. Systemic adverse effects were infrequent and only 1.7% of patients discontinued treatment owing to adverse effects.
Authors: David Saceda-Corralo; Miguel Domínguez-Santas; Sergio Vañó-Galván; Ramon Grimalt Journal: Am J Clin Dermatol Date: 2022-09-28 Impact factor: 6.233
Authors: Carlos Torrado-Salmeron; Almudena Laguna; Alicia Guillén; Miguel G Saro; Antonio Matji; Juan J Torrado; Dolores R Serrano Journal: Pharmaceutics Date: 2022-03-17 Impact factor: 6.321